[1] Siegel R L, Miller K D and Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68(1):7-30. [2] Arnold M, Soerjomataram I, Ferlay J, et al. Global incidence of oesophageal cancer by histological subtype in 2012[J]. Gut, 2015,64(3):381-387. [3] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. [4] Abnet C C, Arnold M, Wei W Q. Epidemiology of esophageal squamous cell carcinoma[J]. Gastroenterology, 2018,154(2):360-373. [5] Ohashi S, Miyamoto S, Kikuchi O, et al. Recent advances from basic and clinical studies of esophageal squamous cell carcinoma[J]. Gastroenterology, 2015,149(7):1700-1715. [6] Shin E, Kashiwagi Y, Kuriu T, et al. Doublecortin-like kinase enhances dendritic remodelling and negatively regulates synapse maturation[J]. Nat Commun, 2013,4:1440. [7] Nakanishi Y, Seno H, Fukuoka A, et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine[J]. Nat Genet, 2013,45(1):98-103. [8] Westphalen C B, Asfaha S, Hayakawa Y, et al. Long-lived intestinal tuft cells serve as colon cancER-initiating cells[J]. J Clin Invest, 2014,124(3):1283-1295. [9] Park S Y, Kim J Y, Choi J H, et al. Inhibition of LEF1-Mediated DCLK1 by niclosamide attenuates colorectal cancer stemness[J]. Clin Cancer Res, 2019,25(4):1415-1429. [10] Chandrakesan P, Yao J, Qu D, et al. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells[J]. Mol Cancer, 2017,16(1):30. [11] Gao T, Wang M, Xu L, et al. DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer[J]. J Cancer Res Clin Oncol, 2016,142(10):2131-2140. [12] Ikezono Y, Koga H, Akiba J, et al. Pancreatic neuroendocrine tumors and EMT behavior are driven by the CSC marker DCLK1[J]. Mol Cancer Res, 2017,15(6):744-752. [13] Li J, Wang Y, Ge J, et al. Doublecortin-like kinase 1(DCLK1) regulates B cell-specific moloney murine leukemia virus insertion site 1(Bmi-1) and is associated with metastasis and prognosis in pancreatic cancer[J]. Cell Physiol Biochem, 2018,51(1):262-277. [14] Whorton J, Sureban S M, May R, et al. DCLK1 is detectable in plasma of patients with barrett's esophagus and esophageal adenocarcinoma[J]. Dig Dis Sci, 2015,60(2):509-513. [15] Weygant N, Qu D, Berry W L, et al. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1[J]. Mol Cancer, 2014,13:103. [16] Harada Y, Kazama S, Morikawa T, et al. Prognostic impact of doublecortin-like kinase 1 expression in locally advanced rectal cancer treated with preoperative chemoradiotherapy[J]. APMIS, 2018,126(6):486-493. [17] Nishio K, Kimura K, Amano R, et al. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma[J]. World J Gastroenterol, 2017,23(31):5764-5772. [18] Abudureheman A, Ainiwaer J, Hou Z, et al. High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma[J]. J Cancer Res Clin Oncol, 2018,144(6):1025-1035. [19] Chandrakesan P, Weygant N, May R, et al. DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition[J]. Oncotarget, 2014,5(19):9269-9280. [20] Ge Y, Weygant N, Qu D, et al. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer[J]. Int J Cancer, 2018,143(5):1162-1175. [21] Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells[J]. Science, 2014,343(6166):84-87. [22] Boettcher M and McManus M T. Choosing the right tool for the Job:RNAi, TALEN, or CRISPR[J]. Mol Cell, 2015,58(4):575-585. |